{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:08:30Z","timestamp":1765609710508},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jns.2016.05.019","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T17:55:32Z","timestamp":1463162132000},"page":"149-154","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response"],"prefix":"10.1016","volume":"366","author":[{"given":"Gulfer","family":"Atasayar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isil Ezgi","family":"Eryilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necdet","family":"Karli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unal","family":"Egeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Zarifoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah","family":"Cecener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Taskapilioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berrin","family":"Tunca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oznur","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Secil","family":"Ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulcin","family":"Tezcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Ezgi","family":"Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2002","series-title":"Headache in Clinical Practise","author":"Silberstein","key":"10.1016\/j.jns.2016.05.019_bb0005"},{"key":"10.1016\/j.jns.2016.05.019_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ncl.2008.11.007","article-title":"Preventive migraine treatment","volume":"27","author":"Silberstein","year":"2009","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2016.05.019_bb0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11940-008-0003-3","article-title":"Update on the prophylaxis of migraine","volume":"10","author":"Schurks","year":"2008","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2016.05.019_bb0020","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1468-1331.2006.01411.x","article-title":"EFNS guideline on the drug treatment of migraine-report of an EFNS task force","volume":"13","author":"Evers","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2016.05.019_bb0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","article-title":"Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations","volume":"1986","author":"Loder","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.jns.2016.05.019_bb0030","series-title":"Historical Aspects of Pharmacogenetics, New York","first-page":"1","article-title":"Pharmacogenemics: drugs and the pharmacceutical science","author":"Bertilson","year":"2001"},{"key":"10.1016\/j.jns.2016.05.019_bb0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytocrome P450 and applications in drug therapy the past, present and future","volume":"25","author":"Ingelman","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2016.05.019_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF01570737","article-title":"Localization of multidrug resistance-associated DNA sequences to human chromosome 7","volume":"12","author":"Fojo","year":"1986","journal-title":"Somat. Cell Mol. Genet."},{"key":"10.1016\/j.jns.2016.05.019_bb0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clpt.2005.08.015","article-title":"Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists","volume":"78","author":"Babaoglu","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2016.05.019_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","article-title":"MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity","volume":"11","author":"Ameyaw","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jns.2016.05.019_bb0055","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2016.05.019_bb0060","article-title":"Lack of association between multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug resistant epilepsy","volume":"11","author":"Saygi","year":"2011","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.jns.2016.05.019_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/cp.1999.v66.100072001","article-title":"Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population","volume":"66","author":"Aynacioglu","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2016.05.019_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","article-title":"Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations","volume":"7","author":"Goldstein","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jns.2016.05.019_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2016.05.019_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11033-006-9022-x","article-title":"Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey","volume":"33","author":"Turgut","year":"2006","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jns.2016.05.019_bb0095","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4238\/vol7-4gmr496","article-title":"Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population","volume":"28","author":"Gumus-Akay","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.jns.2016.05.019_bb0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2125.2008.03189.x","article-title":"MDR1 genotypes do not influence the absorption of a single oral dose of 600mg valacyclovir in healthy Chinese Han ethnic males","volume":"66","author":"Zhang","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2016.05.019_bb0105","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jns.2016.05.019_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000100959","article-title":"Frequency of mutated allele CYP2D6*4 in the Turkish population","volume":"79","author":"Koseler","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.jns.2016.05.019_bb0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.forsciint.2012.07.012","article-title":"The frequencies of mutated alleles of CYP2D6 gene in a Turkish population","volume":"222","author":"Serin","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jns.2016.05.019_bb0120","first-page":"703","article-title":"Epidemiologic and clinical aspects of Behcet's disease in a defined area of Northwestern Spain, 1988\u20131997","volume":"27","author":"Gonzalez-Gay","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2016.05.019_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-4632.2007.02957.x","article-title":"Cytochrome P450 polymorphisms in patients with Behcet's disease","volume":"46","author":"Tursen","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.jns.2016.05.019_bb0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-011-1151-z","article-title":"Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood","volume":"68","author":"Gumus","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2016.05.019_bb0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.braindev.2013.01.016","article-title":"Multidrug resistance 1 (MDR1) 3435C\/T genotyping in childhood drug- resistant epilepsy","volume":"36","author":"Saygi","year":"2014","journal-title":"Brain Dev."},{"key":"10.1016\/j.jns.2016.05.019_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000109264","article-title":"Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey","volume":"59","author":"Ozgon","year":"2008","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jns.2016.05.019_bb0145","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eplepsyres.2014.03.019","article-title":"The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs","volume":"108","author":"Li","year":"2014","journal-title":"Epilepsy Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16302787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16302787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T22:20:50Z","timestamp":1536704450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16302787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":27,"alternative-id":["S0022510X16302787"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.05.019","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}